“…Indeed, some of these compounds are already in clinical trials; others have been tested in vitro in tumour cell lines or in vivo in preclinical models for different neoplasms. Some of these molecules are mastoparan‐like peptides (Jones et al ., ), 4‐( N ‐(Sglutathionylacetyl)amino)phenylarsonous acid (Elliott et al ., ), ursolic acid (Lu et al ., ), betulinic acid (Fulda et al ., ; Potze et al ., ), B4G2 (an hydroxybetulinic acid derivative) (Yao et al ., ), triterpenoid derivatives (Laszczyk, ; Serafim et al ., ), curcumin (Qiu et al ., ), lonidamine (Lena et al ., ), ABT‐737 (a BH3 mimetic) (Yu et al ., ), the K + /H + antiporter salinomycin (Manago et al ., ; Qin et al ., ), berberine (Shen et al ., ), ebselen (Pavon et al ., ), the gold complex AUL‐12 (Chiara et al ., ), icaritin (Zhou et al ., ), EM20‐25 (Milanesi et al ., ) and ferutinin (Ilyich et al ., ). It has to be stressed that in most cases, possible side effects can be envisioned as opening of the PTP might lead to loss of mitochondrial function in healthy cells as well.…”